In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Y-Mabs Therapeutics Inc (YMAB). The company’s shares opened today at $23.07.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.9% and a 42.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Y-Mabs Therapeutics Inc with a $40 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31 and a one-year low of $15.17. Currently, Y-Mabs Therapeutics Inc has an average volume of 168.2K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
